EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trypstatin as a Novel TMPRSS2 Inhibitor with Broad‐Spectrum Efficacy against Corona and Influenza Viruses

Jan Lawrenz iD, Lukas Wettstein iD, Armando Rodríguez Alfonso iD, Rayhane Nchioua, Pascal von Maltitz iD, Dan Pascal Jean Albers iD, Fabian Zech iD, Julie Vandeput iD, Lieve Naesens iD, Giorgio Fois iD, Veronika Neubauer, Nico Preising und 13 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202506430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jan Lawrenz und 24 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany. Hauptthemen laut MEDLINE: Serine Endopeptidases, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Interdisciplinary Doctoral Program in Medicine of the University Hospital Tübingen, Heisenberg Program of the German Research Foundation, DFG Major Research Instrumentation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory viruses, such as SARS‐CoV‐2 and influenza, exploit host proteases like TMPRSS2 for entry, making TMPRSS2 a prime antiviral target. Here, the identification and characterization of Trypstatin, a 61‐amino acid Kunitz‐type protease inhibitor derived from human hemofiltrate are reported. Trypstatin inhibits TMPRSS2 and related proteases with high potency, exhibiting half‐maximal inhibitory concentration values in the nanomolar range, comparable to the small molecule inhibitor camostat mesylate. In vitro assays demonstrate that Trypstatin effectively blocks spike‐driven entry of SARS‐CoV‐2, SARS‐CoV‐1, MERS‐CoV, and hCoV‐NL63, as well as hemagglutinin‐mediated entry of influenza A and B viruses. In primary human airway epithelial cultures, Trypstatin significantly reduces SARS‐CoV‐2 replication and retained activity in the presence of airway mucus. In vivo, intranasal administration of Trypstatin to SARS‐CoV‐2‐infected Syrian hamsters reduces viral titers and alleviates clinical symptoms. These findings highlight Trypstatin's potential as a broad‐spectrum antiviral agent against TMPRSS2‐dependent respiratory viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Serine EndopeptidasesSARS-CoV-2Antiviral AgentsAnimalsHumansCOVID-19 Drug TreatmentMesocricetusVirus InternalizationCricetinaeCOVID-19Influenza A virusVirus Replication

Stichwörter der Autor:innen

TMPRSS2antiviralscoronavirusesemerging viruseshost immune responseinfluenza virusesproteases

Substanzen

TMPRSS2 protein, humanSerine EndopeptidasesAntiviral Agents

Autor:innen und Institutionen

  • Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.
  • Core Facility Functional Peptidomics, Ulm University Medical Center, 89081, Ulm, Germany.
  • Core Unit Mass Spectrometry and Proteomics, Ulm University Medical Center, 89081, Ulm, Germany.
  • Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, 3000, Leuven, Belgium.
  • Institute of General Physiology, Ulm University, 89081, Ulm, Germany.
  • Chair of Computational Bioengineering, Faculty of Biochemical and Chemical Engineering, Technical University of Dortmund, 44227, Dortmund, Germany.

ORCID-Profile: Jan Lawrenz, Lukas Wettstein, Armando Rodríguez Alfonso, Pascal von Maltitz, Dan Pascal Jean Albers, Fabian Zech, Julie Vandeput, Lieve Naesens, Giorgio Fois, Yasser Almeida-Hernandez, Peter Braubach, Manfred Frick, Frank Kirchhoff, Annelies Stevaert, Jan Münch

Förderung

  • Interdisciplinary Doctoral Program in Medicine of the University Hospital Tübingen
  • Heisenberg Program of the German Research Foundation
  • DFG Major Research Instrumentation Program
  • Baden-Württemberg Stiftung
  • Bundesministerium für Bildung und Forschung
  • Deutsche Forschungsgemeinschaft
  • Deutsches Zentrum für Infektionsforschung

Zitieren

APA

Lawrenz, J., Wettstein, L., Rodríguez Alfonso, A., Nchioua, R., von Maltitz, P., Albers, D. P. J., Zech, F., Vandeput, J., Naesens, L., Fois, G., Neubauer, V., Preising, N., Schmierer, E., Almeida-Hernandez, Y., Petersen, M., Ständker, L., Wiese, S., Braubach, P., Frick, M., …, & Münch, J. (2025). Trypstatin as a Novel TMPRSS2 Inhibitor with Broad‐Spectrum Efficacy against Corona and Influenza Viruses. Advanced Science. https://doi.org/10.1002/advs.202506430

Vancouver

Lawrenz J, Wettstein L, Rodríguez Alfonso A, Nchioua R, von Maltitz P, Albers DPJ, et al. Trypstatin as a Novel TMPRSS2 Inhibitor with Broad‐Spectrum Efficacy against Corona and Influenza Viruses. Advanced Science. 2025. doi:10.1002/advs.202506430

BibTeX
@article{Lawrenz2025,
  author = {Lawrenz, Jan and Wettstein, Lukas and Rodríguez Alfonso, Armando and Nchioua, Rayhane and von Maltitz, Pascal and Albers, Dan Pascal Jean and Zech, Fabian and Vandeput, Julie and Naesens, Lieve and Fois, Giorgio and Neubauer, Veronika and Preising, Nico and Schmierer, Emilia and Almeida-Hernandez, Yasser and Petersen, Moritz and Ständker, Ludger and Wiese, Sebastian and Braubach, Peter and Frick, Manfred and Barth, Eberhard and Sauter, Daniel and Kirchhoff, Frank and Sanchez-Garcia, Elsa and Stevaert, Annelies and Münch, Jan},
  title = {Trypstatin as a Novel TMPRSS2 Inhibitor with Broad‐Spectrum Efficacy against Corona and Influenza Viruses},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202506430}
}
Kostenlos starten →